USA flag logo/image

An Official Website of the United States Government

Contaminate Removal For Laboratory Pharmaceutical Synthesis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93795
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
GM084478
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Compact Membrane Systems, Inc.
335 Water Street Newport, DE 19804-2410
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Contaminate Removal For Laboratory Pharmaceutical Synthesis
Agency: HHS
Contract: 1R43GM084478-01A1
Award Amount: $127,581.00
 

Abstract:

DESCRIPTION (provided by applicant): Most organic pharmaceutical chemical syntheses are done in organic solvents. Oxygen and/or water contaminants in organic solvents will destroy many organic reactants and organometallic reagents and catalysts. As such, t he removal of oxygen and water are critical to successful organic synthesis. Unfortunately both oxygen and water are ubiquitous and significant effort must be introduced to both remove oxygen and water and continue to keep them out of the system. Nearly ev ery organic synthesis laboratory in the United States has a system for the removal of oxygen and water from solvents. Laboratories have several special concerns with respect to the purification of solvents. The three major concerns associated with oxygen a nd water removal from solvents are safety, cost and space considerations. Traditionally, organic solvents have been purified by distillation from reactive metals. This Phase I project will develop a membrane product and process to remove dissolved oxygen a nd water from reaction solvents and reactants. This concern for oxygen and water is especially true in laboratory synthesis. Compact Membrane Systems, Inc. proposes a novel membrane product and process to address these issues. This membrane will be a compo site structure using a novel porous support and novel dense membrane. The process will both remove the oxygen and water and maintain their removal. The membrane system is in principle universal and very low cost. The removal of oxygen and water from repres entative solvents will be demonstrated. Once the removal of contaminants is completed, enhanced synthesis related to removal of water and oxygen will be demonstrated working with the University of Delaware. Compact Membrane Systems has numerous industrial and university partners which have shown a strong interest in this technology. These partners will be helpful in the Phase I program and subsequent Phase II activity and commercialization. PUBLIC HEALTH RELEVANCE: This project will develop a membran e product and process to remove dissolved oxygen and water from reaction solvents and reactants. The process will both remove the oxygen and water and maintain their removal. The membrane system is in principle universal and very low cost. This development will represent an application of CMS membrane technology that has considerable significance to production costs related to pharmaceutical manufacturing.

Principal Investigator:

John J. Bowser
3029997996
JOHN.BOWSER@COMPACTMEMBRANE.COM

Business Contact:

Louis Dinetta
rtierney@compactmembrane.com
Small Business Information at Submission:

COMPACT MEMBRANE SYSTEMS, INC.
COMPACT MEMBRANE SYSTEMS, INC. 335 WATER STREET NEWPORT, DE 19804

EIN/Tax ID: 510348256
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No